ダウンロード数: 200

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
66_10_357.pdf948.25 kBAdobe PDF見る/開く
タイトル: 治療中断後に腫瘍縮小が続きCRとなった右精巣腫瘍・多発転移の1例
その他のタイトル: A Case of Testicular Tumor with Multiple Metastasis Leading to Complete Response after Treatment Interruption
著者: 勝又, 有記  KAKEN_name
佐藤, 真彦  KAKEN_name
大竹, 航太郎  KAKEN_name
千葉, 大豪  KAKEN_name
今野, 将人  KAKEN_name
竹本, 淳  KAKEN_name
星, 宣次  KAKEN_name
沼畑, 健司  KAKEN_name
著者名の別形: Katsumata, Yuki
Satou, Masahiko
Otake, Kotaro
Chiba, Daigo
Konno, Masato
Takemoto, Jun
Hoshi, Senji
Numahata, Kenji
キーワード: Testicular tumor
Treatment interruption
Complete response
Residual tumor
発行日: 31-Oct-2020
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要
巻: 66
号: 10
開始ページ: 357
終了ページ: 362
抄録: A 39-year-old man experiencing cranial nerve symptoms was referred to our neurosurgery department after a brain tumor was detected on computed tomography (CT) scans at a local hospital. Due to convulsive symptoms, the patient was admitted to our hospital for detailed examination. The patient was diagnosed with right testicular tumor, multiple brain metastases, multiple lung metastases and right kidney metastases, and was transferred to our urology department. Since the testicular tumor was staged as IIIC and identified as poor prognosis by the International Germ Cell Consensus classification (IGCCC), Bleomycin Etoposide Cisplatin (BEP) chemotherapy was initiated prior to surgery. A right high orchiectomy was performed after two courses of BEP chemotherapy. Histopathology revealed mixed germ cell tumors (seminoma and/or embryonal carcinoma+teratoma) along with the following results : ly (−) ; Intratubular Malignant Germ Cells (ITMGC) (+, viable) ; tunica albuginea invasion (−) ; spermatic cord invasion (−) ; tumor size (73× 50×45 mm). Two additional courses of BEP chemotherapy and two courses of Paclitaxel Ifomaide Cisplatin(TIP) chemotherapy were performed successively. The CT revealed metastatic lesions shrinking steadily but the metastatic foci still remained. Since tumor markers were not negative, continuous chemotherapy was considered. However, strong side effects were expected, and treatment was discontinued. Since then, the tumors continued to shrink, and the tumor markers became negative. Currently, the patient maintains complete response and is being followed-up.
著作権等: 許諾条件により本文は2021/11/01に公開
DOI: 10.14989/ActaUrolJap_66_10_357
URI: http://hdl.handle.net/2433/259373
PubMed ID: 33271650
出現コレクション:Vol.66 No.10

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。